Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Jerome Lewis Avorn, M.D.

Co-Author

This page shows the publications co-authored by Jerome Avorn and Niteesh Choudhry.
Connection Strength

6.918
  1. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol. 2011 Feb 15; 57(7):784-91.
    View in: PubMed
    Score: 0.473
  2. Funding for medical education: maintaining a healthy separation from industry. Circulation. 2010 May 25; 121(20):2228-34.
    View in: PubMed
    Score: 0.450
  3. The economic consequences of non-evidence-based clopidogrel use. Am Heart J. 2008 May; 155(5):904-9.
    View in: PubMed
    Score: 0.384
  4. Using computer-based decision support to close the "know do" gap in lipid-lowering therapy. Circulation. 2008 Jan 22; 117(3):336-7.
    View in: PubMed
    Score: 0.382
  5. Over-the-counter statins. Ann Intern Med. 2005 Jun 07; 142(11):910-3.
    View in: PubMed
    Score: 0.319
  6. Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. Am J Obstet Gynecol. 2016 09; 215(3):353.e1-353.e18.
    View in: PubMed
    Score: 0.168
  7. Medication adherence and healthcare disparities: impact of statin co-payment reduction. Am J Manag Care. 2015 Oct; 21(10):696-704.
    View in: PubMed
    Score: 0.163
  8. Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction. Circ Cardiovasc Qual Outcomes. 2015 May; 8(3):252-9.
    View in: PubMed
    Score: 0.158
  9. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015 Mar 17; 162(6):407-19.
    View in: PubMed
    Score: 0.157
  10. Burden of changes in generic pill appearance. Ann Intern Med. 2014 Dec 02; 161(11):840.
    View in: PubMed
    Score: 0.154
  11. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA Intern Med. 2014 Dec; 174(12):1955-62.
    View in: PubMed
    Score: 0.154
  12. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med. 2014 Jul 15; 161(2):96-103.
    View in: PubMed
    Score: 0.150
  13. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med. 2014 Nov; 127(11):1075-1082.e1.
    View in: PubMed
    Score: 0.148
  14. Five features of value-based insurance design plans were associated with higher rates of medication adherence. Health Aff (Millwood). 2014 Mar; 33(3):493-501.
    View in: PubMed
    Score: 0.145
  15. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2013 Nov; 6(6):724-31.
    View in: PubMed
    Score: 0.143
  16. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J. 2014 Jan; 167(1):51-58.e5.
    View in: PubMed
    Score: 0.142
  17. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ. 2013 Sep 17; 347:f5307.
    View in: PubMed
    Score: 0.141
  18. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med. 2013 Feb 11; 173(3):202-8.
    View in: PubMed
    Score: 0.136
  19. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012 Oct 30; 60(18):1817-24.
    View in: PubMed
    Score: 0.132
  20. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. Health Serv Res. 2012 Dec; 47(6):2097-117.
    View in: PubMed
    Score: 0.132
  21. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012 Jul 01; 5(4):480-6.
    View in: PubMed
    Score: 0.130
  22. Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Europace. 2012 Sep; 14(9):1287-93.
    View in: PubMed
    Score: 0.128
  23. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012 Mar; 125(3):302.e1-7.
    View in: PubMed
    Score: 0.127
  24. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011 Dec 01; 365(22):2088-97.
    View in: PubMed
    Score: 0.124
  25. Conflict of interest in oncology publications: a survey of disclosure policies and statements. Cancer. 2012 Jan 01; 118(1):188-95.
    View in: PubMed
    Score: 0.121
  26. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011 May 09; 171(9):814-22.
    View in: PubMed
    Score: 0.120
  27. The consequences of requesting "dispense as written". Am J Med. 2011 Apr; 124(4):309-17.
    View in: PubMed
    Score: 0.119
  28. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010 Nov; 29(11):1995-2001.
    View in: PubMed
    Score: 0.116
  29. Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Am J Cardiol. 2010 Jun 15; 105(12):1655-60.
    View in: PubMed
    Score: 0.112
  30. Patient, physician, and payment predictors of statin adherence. Med Care. 2010 Mar; 48(3):196-202.
    View in: PubMed
    Score: 0.111
  31. An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomes. Med Care. 2009 Sep; 47(9):1031-5.
    View in: PubMed
    Score: 0.107
  32. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2009 Sep; 2(5):429-36.
    View in: PubMed
    Score: 0.106
  33. Is there a relationship between patient beliefs or communication about generic drugs and medication utilization? Med Care. 2009 Mar; 47(3):319-25.
    View in: PubMed
    Score: 0.103
  34. Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy label. J Gen Intern Med. 2009 May; 24(5):570-8.
    View in: PubMed
    Score: 0.103
  35. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr; 157(4):613-9.
    View in: PubMed
    Score: 0.103
  36. Comparison of the impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial on prescribing patterns: a time-series analysis. Ann Pharmacother. 2008 Nov; 42(11):1563-72.
    View in: PubMed
    Score: 0.100
  37. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008 Jul; 156(1):31-6.
    View in: PubMed
    Score: 0.098
  38. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008 Mar 11; 117(10):1261-8.
    View in: PubMed
    Score: 0.096
  39. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood). 2007 Jan-Feb; 26(1):186-94.
    View in: PubMed
    Score: 0.089
  40. General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment. Patient. 2019 04; 12(2):235-246.
    View in: PubMed
    Score: 0.052
  41. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. J Comp Eff Res. 2018 01; 7(1):57-66.
    View in: PubMed
    Score: 0.048
  42. Medicaid prescription limits: policy trends and comparative impact on utilization. BMC Health Serv Res. 2016 Jan 15; 16:15.
    View in: PubMed
    Score: 0.042
  43. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015 Nov; 52(Pt A):14-8.
    View in: PubMed
    Score: 0.041
  44. Paying physicians to prescribe generic drugs and follow-on biologics in the United States. PLoS Med. 2015 Mar; 12(3):e1001802.
    View in: PubMed
    Score: 0.039
  45. Patients' preferences in anticoagulant therapy: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2014 Nov; 7(6):912-9.
    View in: PubMed
    Score: 0.038
  46. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014 Sep 16; 161(6):400-7.
    View in: PubMed
    Score: 0.038
  47. Unintended consequences of a Medicaid prescription copayment policy. Med Care. 2014 May; 52(5):422-7.
    View in: PubMed
    Score: 0.037
  48. Equity in the receipt of oseltamivir in the United States during the H1N1 pandemic. Am J Public Health. 2014 Jun; 104(6):1052-8.
    View in: PubMed
    Score: 0.037
  49. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2014 Feb; 29(2):320-7.
    View in: PubMed
    Score: 0.035
  50. Warnings without guidance: patient responses to an FDA warning about ezetimibe. Med Care. 2012 Jun; 50(6):479-84.
    View in: PubMed
    Score: 0.032
  51. Trouble getting started: predictors of primary medication nonadherence. Am J Med. 2011 Nov; 124(11):1081.e9-22.
    View in: PubMed
    Score: 0.031
  52. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010 Nov 16; 153(10):633-40.
    View in: PubMed
    Score: 0.029
  53. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009 Dec 08; 120(23):2322-9.
    View in: PubMed
    Score: 0.027
  54. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007 Dec; 27(6):707-10.
    View in: PubMed
    Score: 0.024
  55. The variability and quality of medication container labels. Arch Intern Med. 2007 Sep 10; 167(16):1760-5.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.